Program

Vaccine Technology IV

May 20-25, 2012
Albufeira, Portugal

Program Co-Chairs

John G. Auniņš, Ph.D.
Barry C. Buckland, Ph.D.
Kathrin Jansen, Ph.D.
Paula Marques Alves, Ph.D.

ECI

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004, USA
Phone: 1 - 212 - 514 - 6760, Fax: 1 - 212 - 514 - 6030
www.engconfintl.org – info@engconfintl.org
Grande Real Santa Eulalia Resort & Hotel Spa
Praia de Santa Eulalia
( Secondary road from Albufera town to Olhos D’Agua village )
8200-916 Albufera
Algarve / Portugal
Telephone +351 289 598 020
Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

ECI BOARD MEMBERS

Barry C. Buckland, President
   Peter Gray
   Michael King
   Raymond McCabe
   David Robinson
   William Sachs
   Eugene Schaefer
   P. Somasundaran
   Deborah Wiley

Chair of ECI Conferences Committee: William Sachs

ECI Technical Liaison for this conference: John Aunins

ECI Executive Director: Barbara K. Hickernell

ECI Associate Director: Kevin M. Korpics

©Engineering Conferences International
### Organizing Committee Members:

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuel Carrondo</td>
<td>IBET, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>Leda Castilho</td>
<td>Federal Univ. of Rio de Janeiro, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>Manon Cox</td>
<td>Protein Sciences, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Anne DeGroot</td>
<td>EpiVax, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Debbie Drane</td>
<td>CSL Limited, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Mark Feinberg</td>
<td>Merck, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Nathalie García</td>
<td>GlaxoSmithKline, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>Akshay Goel</td>
<td>Hilleman Labs, India</td>
<td>India</td>
</tr>
<tr>
<td>Phillip Gomez, III</td>
<td>PriceWaterhouseCoopers, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Bruce Green</td>
<td>Pfizer, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Mike Hoare</td>
<td>University College London, UK</td>
<td>UK</td>
</tr>
<tr>
<td>Amine Kamen</td>
<td>National Research Council, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>David Kaslow</td>
<td>PATH, Malaria Vaccine Initiative, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Susana Levy</td>
<td>Biogénesis-Bagó, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td>John Lewis</td>
<td>Crucell, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Fiona MacLaughlin</td>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Luis Maranga</td>
<td>Novartis Vaccines &amp; Diagnostics (NV&amp;D), USA</td>
<td>USA</td>
</tr>
<tr>
<td>Phil Minor</td>
<td>NIBSC, UK</td>
<td>UK</td>
</tr>
<tr>
<td>David Onions</td>
<td>Bioreliance, UK</td>
<td></td>
</tr>
<tr>
<td>Laura Palomares</td>
<td>UNAM, Mexico</td>
<td></td>
</tr>
<tr>
<td>Herve Pinton</td>
<td>Sanofi-Pasteur, France</td>
<td></td>
</tr>
<tr>
<td>Octavio Ramirez</td>
<td>IBT-UNAM, Mexico</td>
<td></td>
</tr>
<tr>
<td>Udo Reichl</td>
<td>Max Planck Institute for Dynamics of Complex Technical Systems, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>George Siber</td>
<td>Genocea, USA</td>
<td>USA</td>
</tr>
<tr>
<td>David Weiner</td>
<td>University of Pennsylvania, USA</td>
<td>USA</td>
</tr>
</tbody>
</table>

### Poster Chairs:

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tarit K. Mukhopadhyay</td>
<td>University College London, UK</td>
<td>UK</td>
</tr>
<tr>
<td>Héla Kallel</td>
<td>Institut Pasteur de Tunis, Tunisia</td>
<td>Tunisia</td>
</tr>
</tbody>
</table>
Conference Sponsors

The Bill & Melinda Gates Foundation

Merial, Ltd.
Pfizer
PPD
Sartorus Stedim Biotech

ATMI Life Sciences
BIA Separations
CSL
GE Healthcare Life Sciences

Merck and Co., Inc.
Novartis Vaccines and Diagnostics

AERAS
Inovio
Nanoimaging Services
Pall

ABEC, Inc.
Biologics Consulting Group, Inc.
DASGIP
PBS Biotech
PlasmidFactory GmbH Co. KG
Sunday, May 20, 2012

15:30 – 18:00  Conference check-in
18:00 – 18:30  Welcoming Remarks and Opening of the Conference
               Conference Chairs Introduction
               Celebrating 50 years of ECI Conferences - John Aunins
18:30 – 19:30  Keynote
               Malaria Vaccines as a model of vaccine development
               David Kaslow, PATH, Malaria Vaccine Initiative, USA
19:30 – 20:15  Welcome Reception with Folk Dancing
20:15 – 22:00  Dinner

NOTES

• Technical Sessions will be held in Sala Grande Real.
• Poster Sessions will be held in Grande Real Foyer.
• Most meals will be in the Restaurante do Real. Changes will be announced.
• The conference banquet on Thursday will be held in the Restaurante Santa Eulalia.
• Audiotaping, videotaping and photography of presentations are prohibited.
• Speakers – Please leave at least 5 minutes for questions and discussion.
• Please do not smoke at any conference functions.
• Turn your cellular telephones to vibrate or off during technical sessions.
• After the conference, ECI will send an updated participant list to all participants. Please check your listing now and if it needs updating, you may correct it at any time by logging into your ECI account.
Monday, May 21, 2012

07:00 – 08:30 Breakfast

08:30 – 11:00 **Session I: Vaccine target identification and validation**
Session Chairs:
*George* Siber, Genocea
*David* Weiner, University of Pennsylvania

08:35 – 09:05 Comprehensive T-cell antigen discovery using a genomic approach
Jessica Flechtner, Genocea Biosciences, USA

09:05 – 09:35 Rational design of a fully synthetic nanoparticle-based vaccine for smoking cessation
Takashi Kei Kishimoto, Selecta Biosciences, USA

09:35 – 10:05 Tolerogenic vaccination exploiting apoptotic mechanisms via erythrocyte-to-hepatic targeting
Jeffrey A. Hubbell, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland

10:05 – 10:30 Development of a vaccine against clostridium difficile infection: Design, purification and biological activities of recombinant toxin antigen fragments
Jerzy Karczewski, Merck, USA

10.30 – 11:00 Coffee break

11:00 – 11:30 Molecular deconvolution of the monoclonal antibodies that comprise the serum response to vaccination
George Georgiou, University of Texas, USA

11:30 – 13:10 **Session II: Technology challenges in developing world market (Part 1)**
Session Chairs:
Leda Castilho, Federal University of Rio de Janeiro
Paula Alves, IBET

Sponsored by ATMI Life Sciences

11:30 – 12:00 Instituto Butantan - 111 years producing immunobiologics: New challenges
Jorge Kalil, Instituto Butantan, Brazil

12:00 – 12:20 PATH vaccine global development program
George A. Robertson, PATH, USA

12:20 – 12:50 Recombinant VLP based human vaccines for emerging markets
Qinjian Zhao, Xiamen University, China

12:50 – 13:10 Establishing human vaccine manufacturing in Southern Africa
Morena Makhoana, The Biovac Institute, South Africa

13:10 – 14:00 Lunch
Monday, May 21, 2012 (continued)

14:00 – 15:30  
**Session III: Late stage and recently launched vaccines**  
Session Chairs:  
Nathalie Garcon, GlaxoSmithKline  
Kathrin Jansen, Pfizer

*Sponsored by GE Healthcare Life Sciences*

14:00 – 14:30  
Development of Pfizer bivalent RLP2086 vaccine for prevention of invasive disease caused by *Neisseria Meningitidis* Serogroup B  
Joe Eiden, Pfizer, USA

14:30 – 15:00  
Recombinant influenza vaccine  
Manon Cox, Protein Sciences, USA

15:00 – 15:30  
Process understanding approach for a late-stage recombinant protein vaccine produced in *Saccharomyces Cerevisiae*  
José Manuel Otero, Merck, USA

15:30 – 17:00  
*ad hoc* sessions, free time

17:00 – 17:30  
**Session II: Technology challenges in developing world market (Part 2)**

17:00 – 17:30  
Challenges in development of an anti-idiotypic cancer vaccine  
Adolfo Castillo Vitlloch Center of Molecular Immunology, Cuba

17:30 – 18:00  
Expectation of China’s contribution to world vaccine development and supplies: Status, strategy and international approach  
Li Shi, Shanghai Zerun Biotechnology Ltd. Co., China

18:00 – 18:20  
Rabies virus-like particles expressed in HEK293 cells  
Diego Fontana, Universidad Nacional del Litoral, Argentina

18:20 – 18:40  
The role of public-private partnerships in advancing vaccine technologies and improving vaccine effectiveness and delivery for developing countries  
Ray Cummings, PATH, USA

18:40 – 19:00  
Challenges in clinical batches production of malaria vaccines  
Nicolas Havelange, European Vaccine Initiative, Germany

19:00 – 20:30  
Dinner

20:30 – 22:30  
Poster Reception
Tuesday, May 22, 2012

07:00 – 08:30  Breakfast

08:30 – 10:30  Session IV: Vaccine stability, characterization and delivery  
Session Chairs:  
Debbie Drane, CSL Limited  
Robert Evans, Merck, USA

08:30 – 08:50  Optimization of vaccine thermal stability through high-throughput formulation - Development of a screening platform and application to measles vaccine  
Iain McFadyen, ex-Transform Pharmaceuticals, Inc., USA

08:50 – 09:10  Nanopatches for targeted vaccine delivery to skin: Improving vaccines  
Mark Kendall, AIBN, University of Queensland, Australia

09:10 – 09:30  Formulation and stability studies for a Chikungunya virus-like particle (Chikv VLP) based vaccine  
Richard Schwartz, Vaccine Production Program Laboratory/VRC/NIAID, USA

09:30 – 09:50  High throughput formulation design for a stable lyophilized virus-like particle vaccine against Group A Streptococcus  
Yap Pang Chuan, AIBN, University of Queensland, Australia

09:50 – 10:10  Challenges in optimizing formulations for multi-antigen vaccines  
Lakshmi Khandke, Pfizer, USA

10:10 – 10:30  Stabilization technology for viral vaccines and adjuvanted vaccines  
Stephen Ward, StabiliTech Ltd., UK

10:30 – 11:00  Coffee break

11:00 – 13:00  Session V: Veterinary vaccines  
Session Chairs:  
Robert Nordgren, Merial  
Ian Tarpey, Merck

11:00 – 11:30  A new successful vaccine against babesiosis: Any use for malaria?  
Theo Schetters, Merck, USA

11:30 – 12:00  Leishmaniasis vaccine development: Animals as models and patients  
Steven Reed, IDRI

12:00 – 12:30  Rift valley fever: Next generation vaccines for an old foe  
Brian Bird, CDC, USA

12:30 – 12:50  Functional genomics as a tool to define a molecular signature of effective vaccination against foot and mouth disease virus  
Jose A. Chabalgoity, Departamento de Desarrollo Biotecnologico, Facultad de Medicina, Universidad de la Republica, Uruguay

13:00 – 14:30  Lunch

14:30 – 15:30  ad hoc sessions, free time
Tuesday, May 22, 2012 (continued)

15:30 – 19:00  **Session VI: Oncology and therapeutic vaccines**  
Session Chairs:  
John Aunins, Janis Biologics  
Amine Kamen, National Research Council

15:35 – 16:15  **Keynote: Oncolytic viruses as cancer therapies**  
Stephen Russell, Mayo Clinic, USA

16:15 – 16:35  **Vaccine potential of replicating oncolytic virus vectors**  
John C. Bell, Ottawa Hospital Research Institute, Canada

16:35 – 17:05  **The CMC challenges in developing an oncolytic immunotherapy**  
Colin Love, Amgen, USA

17:05 – 17:30  Coffee break

17:30 – 17:50  **Development of novel cell-based immunotherapies**  
Madhusudan Peshwa, Maxcyte, USA

17:50 – 18:10  **Process development for a peptide conjugated qbeta virus-like particle (VLP) vaccine**  
Jennifer Thorn, Pfizer, USA

18:10 – 18:30  **Chimpanzee ad vector technology platform for prophylactic and therapeutic genetic vaccine applications**  
Stefano Colloca, Okairos, Italy

18:30 – 18:50  **Cervical cancer immunotherapy: Induction of HPV specific CTLs in human volunteers after VGX-3100 immunization**  
Niranjan Y. Sardesai, Ph.D., Inovio Pharmaceuticals, Inc., USA

19:00 – 20:30  Dinner

20:30 – 22:30  Poster Reception
Wednesday, May 23, 2012

07:00 – 08:30   Breakfast

08:30 – 12:40   **Session VII: Bioprocess development and analytical tools**
Session Chairs:
Luis Maranga, Novartis Vaccines & Diagnostics (NV&D)
Laura Palomares, UNAM, Mexico

*Sponsored by BIA Separations*

8:30 – 09:00   *Microbial fermentation: New tools to speed-up vaccine antigen development and increase process knowledge*
Catherine Jourdat, Sanofi Pasteur, France

09:00 – 09:30   *Bacterial expression of a VLP Sub-unit for rapid and cheap influenza vaccination*
Anton Middelberg, University of Queensland, Australia

09:30 – 10:00   *High cell density cultivations for influenza virus production*
Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

10:00 – 10:20   *RMCE-based SF9 cell factory for production of multimeric VLPs*
Ana P. Teixeira, ITQB-UNL/IBET, Portugal

10:20 – 10:50   Coffee break

10:50 – 11:20   *Systematic characterization of adventitious agent testing for biological medicinal products*
Rebecca Sheets, NIH, National Institute of Allergy & Infectious Diseases, USA

11:20 – 11:50   *Automation and multiplexing of immunoassays: Improving precision and throughput*
Ilia Tikhonov, PPD, USA

11:50 – 12:10   *Developing a suite of analytics to support process development for the manufacture of polysaccharides*
Aaron Noyes, University College London, UK

12:10 – 12:40   *Prediction of serum bactericidal and opsonophagocytosis using a high-throughput flow cytometric antibody-mediated complement binding assay for Neisseria Meningitidis*
Andrew Gorringe, Health Protection Agency, UK

12:40 – 14:00   Lunch

14:00 – 15:00   *ad hoc* sessions

15:00 – 16:30   **Session VIII: Biodefense, pandemic & emerging disease vaccines: (Part 1)**
Session Chairs:
Barry Buckland, University College London
Phil Gomez, PriceWaterhouseCoopers

15:00 – 15:30   *Development of vaccines for Ebolavirus*
Nancy Sullivan, NIH, USA
Wednesday, May 23, 2012 (continued)

15:30 – 16:00  BARDA vaccine program  
Bob Huebner, BARDA, USA

16:00 – 16:30  Sabin-IPV process development and optimization for cost-price reduction and technology transfer purposes  
Wilfried A.M. Bakker, National Institute for Public Health and the Environment (RIVM), Netherlands

17:00 – 22:00  Excursion (Dinner on own)
Thursday, May 24, 2012

07:00 – 08:30  Breakfast

08:30 – 13:00  **Session IX: New technologies and approaches**

Session Chairs:
Mike Hoare, University College London
Herve Pinton, Sanofi Pasteur

*Sponsored by Sartorius Stedim Biotech*

08:30 – 09:00  **Bacterium-like particles as delivery vehicles for multimeric antigens**
Kees Leenhouts, Mucosis B.V., Netherlands

09:00 – 09:20  **Production of bacterial outer membrane vesicles for antigen delivery**
Bas van de Waterbeemd, RIVM/Vaccinology/Process Development, Netherlands

09:20 – 09:50  **Multiply activated VLP influenza vaccines**
James Swartz, Stanford University, USA

09:50 – 10:10  **Endotoxin-free E. Coli hosts for vaccine discovery and production**
David Bramhill, Research Corporation Technologies, USA

10:10 – 10:30  **Micro-scale vaccine development – A tools set for success**
Tarit K. Mukhopadhyay, University College London, UK

10:30 – 11:00  Coffee break

11:00 – 11:30  **Novel glycoconjugate vaccines based on rationally designed synthetic carbohydrate antigens**
A. Stewart Campbell, Ancora Pharmaceuticals, Inc., USA

11:30 – 12:00  **Automated single-use centrifugation and cell-washing solution for vaccine manufacturing**
Sunil Mehta, kSep Systems, LLC

12:00 – 12:30  **Utilizing ‘omics tools to investigate the impact of process changes on product quality in cell culture-based influenza vaccine production**
Erdmann Rapp, Max Planck Institute for Dynamics of Complex Technical Systems

12:30 – 13:00  **Monolithic columns for purification and in-process control of viruses and virus-like particles**
Lidija Urbas, BIA Separations, Slovenia

13:00 – 14:00  Lunch

14:00 – 15:00  *ad hoc* sessions, free time

15:00 – 17:20  **Session VIII: Biodefense, pandemic & emerging disease vaccines: (Part 2)**

15:00 – 15:25  **Plant-made influenza virus-like particles: For pandemic and beyond**
Nathalie Charland, Medicago, Canada

15:25 – 15:50  **Flunisyn: Advanced development of a synthetic universal influenza t-cell vaccine**
Campbell Bunce, PhD, Immune Targeting Systems (ITS) Ltd., UK
Thursday, May 24, 2012 (continued)

15:50 – 16:15  **Purification of cell-based influenza H5N1 viruses by liquid chromatography technologies**
Alan Yung-Chih Hu, National Institute of Infectious Diseases and Vaccinology, NHRI, Taiwan

16:15 – 16:40  **Viral sensitizer technology improves yield of modified vaccinia ankara from available cell substrates**
Fabrice Le Boeuf, Ottawa Hospital Research Institute, Center for Innovative Cancer Therapeutics, Canada

16:40 – 17:05  **Suspension vero cells (SVERO) for poliovirus production: Effect of culture passage on growth kinetics and productivity**
Guillermina Forno, Universidad Nacional del Litoral, Argentina

17:05 – 17:35  Coffee break

17:35 – 18:05  **Keynote**
**Monitoring immune response on a cell by cell basis**
Christopher Love, MIT, USA

19:00 – 24:00  Banquet and closing
Friday, May 25, 2012

07:00 – 10:30 Breakfast and departures
Vaccine Technology IV
Poster List

1. **Development of multivalent protein capsular matrix vaccine (PCMV) technology**  
   Kevin Killeen, Matrivax R&D Corporation, USA

2. **Development and scale-up of a high yield transient transfection platform for the production of a Chikungunya virus-like particle vaccine**  
   Joshua Merritt, National Institutes of Health, USA

3. **Visualization of domain structure and flexibility of proteins and protein complexes using TEM**  
   Bridget Carragher, NanolImaging Services, Inc., USA

4. **Impact of the ligand density on adenovirus serotype 5 purification using membrane chromatography.**  
   Piergiuseppe Nestola, IBET/ITQB-UNL, Portugal

5. **Towards a better understanding of on-line multifrequency permittivity measurements of adherent Vero cell cultures in perfused processes**  
   A. El Wajgali, CNRS-Université de Lorraine, France

6. **Universal influenza virus vaccine based on the conserved stalk domain of the hemagglutinin**  
   Florian Krammer, Mount Sinai School of Medicine, USA

7. **Rapid cell line selection and process development using high-throughput technologies, design of experiments (DOE) and quality by design**  
   Tiffany D Rau, Rau and Associates, USA

8. **New approaches in intensification and optimization of integrated malaria vaccine production with Pichia pastoris**  
   Jens Fricke, HAW-Hamburg University of Applied Sciences, Germany

9. **Evaluation of critical process parameters and operation range for successful scale up and robust manufacturing of reolysin®**  
   Amine Kamen, National Research Council, Canada

10. **Tetravalent dengue vaccine produced at Instituto Butantan**  
    Vanessa Takinami, Instituto Butantan, Brazil

11. **Pentavalent rotavirus vaccine - stability study**  
    Vanessa Takinami, Instituto Butantan, Brazil
<table>
<thead>
<tr>
<th></th>
<th>Title</th>
<th>Author/Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Analysis and optimization of a sequential malaria vaccine production process with in-situ product removal (ISPR)</td>
<td>Sanja Martens, University of Applied Sciences Hamburg, Germany</td>
</tr>
<tr>
<td>13</td>
<td>Dendritic cell-targeting nanoparticle-based pulmonary vaccines for inducing potent cellular immune responses</td>
<td>Jeffrey A. Hubbell, Ecole Polytechnique Federale de Lausanne (EPFL), Switzerland</td>
</tr>
<tr>
<td>14</td>
<td>Engineering of <em>Escherichia coli</em> strains specifically for plasmid biopharmaceutical production</td>
<td>Geisa A. L. Gonçalves, Instituto Superior Técnico (IST), Portugal</td>
</tr>
<tr>
<td>15</td>
<td>Semliki forest virus expressing rabies virus glycoprotein: Synthesis and protection studies.</td>
<td>Carlos A Pereira, Instituto Butantan, Brazil</td>
</tr>
<tr>
<td>16</td>
<td>Affordable inactivated polio vaccine using modular facilities and disposable technology – potential for local sustainable production of vaccine in low- and middle-income countries</td>
<td>A.G.Lopes, LLB Global Health Solutions Ltd., United Kingdom</td>
</tr>
<tr>
<td>17</td>
<td>Influenza production kinetics in HEK293 cell cultures</td>
<td>Amine Kamen, National Research Council of Canada - Vaccine Program, Canada</td>
</tr>
<tr>
<td>18</td>
<td>Target cells for antibodies detection in rabies vaccine control</td>
<td>Diego Fontana, Universidad Nacional del Litoral, Argentina</td>
</tr>
<tr>
<td>19</td>
<td>A strategy for scale-up of adherent Vero cells using cytodex tm microcarriers and WAVE bioreactor systems</td>
<td>Ann-Christin Magnusson, GE Healthcare, Sweden</td>
</tr>
<tr>
<td>20</td>
<td>Live attenuated influenza virus production in batch high cell density cultivation of suspension AGE1.CR.pix cells</td>
<td>Verena Lohr, Max-Planck-Institute for Dynamics of Complex Technical Systems, Germany</td>
</tr>
<tr>
<td>21</td>
<td>Quantification of GFP-labeled virus-like particles by spectrofluorometry</td>
<td>Francesc Godia, Universitat Autònoma de Barcelona, Spain</td>
</tr>
<tr>
<td>22</td>
<td>Development of serum-free medium supplemented with non-animal derived components for production of virus-like particles in HEK 293 cell cultures</td>
<td>Francesc Godia, Universitat Autònoma de Barcelona, Spain</td>
</tr>
<tr>
<td>23</td>
<td>Investigation into proteolytic clipping of product from manufacturing consistency lots</td>
<td>Michael Kosinski, Merck &amp; Co., Inc., USA</td>
</tr>
<tr>
<td>24</td>
<td>Production of safe transgene delivery vectors- minicircles</td>
<td>Michaela Simcikova, Instituto Superior Técnico, Portugal</td>
</tr>
</tbody>
</table>
25. **An animal component free medium that promotes the growth of various animal cell lines for the production of viral vaccines**
Héla Kallel, Institut Pasteur de Tunis, Tunisia

26. **Study of dengue virus replication in vero cells**
Vanessa Harumi Takinami, Instituto Butantan, Brazil

27. **Development a vectored vaccine against Hepatitis E virus**
Héla Kallel, Institut Pasteur de Tunis, Tunisia

28. **Subunit Leptospiral immunoglobulin-like (Lig) protein vaccine protects against lethal challenge in the hamster model of leptospirosis**
Marco Alberto Medeiros, Oswaldo Cruz Foundation (FIOCRUZ), Brazil

29. **Improvements on peste des petits ruminants vaccine stability during production and storage**
Paula Alves, IBET/ITQB-UNL, Portugal

30. **Production of adenovirus vectors in human amniocyte-derived cells**
Paula Alves, IBET/ITQB-UNL, Portugal

31. **Development of a membrane adsorber-based capture step for the purification of yellow fever virus**
Tania P. Pato, Oswaldo Cruz Foundation (FIOCRUZ), Brazil

32. **Process development and technology transfer of a high yield fermentation process for cgmp production of plasmid DNA vaccines**
Aaron E. Carnes, Nature Technology Corporation, USA

33. **Sensitive methods for evaluation of antibodies for host cell protein analysis and screening of impurities through out a vaccine process**
Christine Sund-Lundström, GE Healthcare Biosciences AB, Sweden

34. **Use of a hydrocyclone as cell retention device in a perfusion process with BHK-21 Cells infected with bovine rabies virus**
Ricardo Medronho, Federal University of Rio de Janeiro, Brazil

35. **Optimization of TRT virus production in bioreactor**
Lídia Garcia, Pfizer Olot S.L.U, Spain

36. **Adenovirus based vaccine formulations: A 5.5-year stability storage study**
Marcos F. Q. Sousa, Universidade Nova de Lisboa, Portugal

37. **In vivo active delivery of antigens to splenic dendritic cells by engineered bio-nanocapsules, hepatitis B virus surface antigen L protein particles**
Hidenori Matsuo, Nagoya University, Japan
38. **Influenza antigen design on virus-like particles**
   Linda Lua, The University of Queensland, Australia

39. **Development of monovalent oral poliovirus vaccines types 1, 2, and 3**
   Marisela Morales Moreno, Laboratorios de Biologicos y Reactivos de Mexico S.A. de C.V. (BIRMEX), Mexico

40. **Linear scalability for viral entities production in icellis™ disposable fixed-bed bioreactor from bench-scale to industrial scale**
   Jean-Christophe Drugmand, ATMI LifeSciences, Belgium

41. **Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: A case study with hepatitis B vaccine**
   Clinton Potter, NanolImaging Services, Inc., USA

42. **Structural tailoring of HEV capsid protein for gaining insights into vaccine design**
   Shaowei Li, Xiamen University, China

43. **Vaccine candidate process verification and performance qualification**
   Jennifer Haas, Merck & Co., Inc., USA

44. **Three VP6 formats: Nanotubes, virus-like particles and VP6 trimers protected mice against rotavirus infection**
   Ana Ruth Pastor, Instituto de Biotecnología-Universidad Nacional Autónoma de México, Mexico

45. **N-glycosylation determines the stability and immunogenicity of recombinant influenza hemagglutinin**
   Laura A. Palomares, Instituto de Biotecnología. Universidad Nacional Autónoma de México, Mexico

46. **Use of yeast extracts containing rotavirus-like particles and soluble rotavirus proteins as a low-cost veterinary vaccine**
   William A. Rodríguez-Limas, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Mexico

47. **Pre-treatment of Japanese encephalitis virus with formaldehyde and glycine improves recovery from flow-through ion-exchange chromatography purification**
   Michael Hughson, University College London, United Kingdom

48. **Control and analysis of quaternary complexity in virus-like particle assembly**
   Yap Pang Chuan, The University of Queensland, Australia

49. **Development of cancer vaccine based on her-1 extracellular domain**
   Adolfo Castillo, Center of Molecular Immunology, Cuba

50. **Characterization of monolithic chromatographic support for phage purification**
   Lidija Urbas, BIA Separations, Slovenia
51. Integration of monolithic analytical columns into the biopharmaceutical manufacturing process to enable fast and real-time HPLC analytical assay both up- and downstream
Lidija Urbas, BIA Separations, Slovenia

52. Different strategies of pDNA purification processes on methacrylate monolithic columns
Daniela Marc, BIA Separations, Slovenia

53. Characterization and immunogenicity of Chikungunya virus-like particle (CHIKV VLP) based vaccine
Richard Schwartz, National Institutes of Health, USA